查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1812281

干癣关节炎治疗市场－全球产业规模、份额、趋势、机会和预测（按药物类别、给药途径、地区和竞争细分，2020-2030 年预测）

Psoriatic Arthritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route of Administration, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024年，全球干癣性关节炎治疗市场规模达97.8亿美元，预计2030年将达到134.8亿美元，复合年增长率为5.69%。这得归功于药物研发的进步、疾病认知度的提升、诊断能力的提升。随着全球医疗保健系统日益认识到干癣性关节炎对生活品质和生产力的影响，治疗方案也不断扩展，以满足患者不断变化的需求。

市场概况
预测期 2026-2030
2024年市场规模 97.8亿美元
2030年市场规模 134.8亿美元
2025-2030年复合年增长率 5.69%
成长最快的领域 非类固醇抗发炎药
最大的市场 北美洲

生物疗法仍然是该市场治疗的基石，提供有针对性的治疗方法，帮助控制发炎并预防关节损伤。这些疗法对中度至重度疾病患者尤其有效，并已在已开发地区和新兴地区广泛采用。创新仍然是塑造该市场未来的关键因素。製药公司正在投资下一代疗法，以提供更高的安全性、更低的给药频率和更高的患者依从性。

关键市场驱动因素

医疗保健产业的成长

主要市场挑战

治疗费用高且经济承受能力差

主要市场趋势

生物製剂和标靶疗法的兴起

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球干癣性关节炎治疗市场的影响

第五章：全球干癣关节炎治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依药物类别（NSAID、DMARD、生物製剂、其他）
    • 依给药途径（外用、口服、注射）
    • 按地区
    • 按公司分类（2024 年）
  • 市场地图

第六章：北美银屑病关节炎治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章：欧洲干癣关节炎治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区干癣关节炎治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章：南美洲干癣关节炎治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲银屑病关节炎治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如有）
  • 最新动态

第十三章：干扰：衝突、流行病与贸易壁垒

第 14 章：全球干癣关节炎治疗市场：SWOT 分析

第 15 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 16 章：竞争格局

  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer, Inc.
  • UCB SA

第 17 章：策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 30721

Global Psoriatic Arthritis Treatment Market was valued at USD 9.78 Billion in 2024 and is expected to reach USD 13.48 Billion by 2030 with a CAGR of 5.69%. This is driven by advancements in drug development, rising disease awareness, and improvements in diagnostic capabilities. As healthcare systems around the world increasingly recognize the impact of psoriatic arthritis on quality of life and productivity, treatment options are expanding to meet the evolving needs of patients.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 9.78 Billion
Market Size 2030USD 13.48 Billion
CAGR 2025-20305.69%
Fastest Growing SegmentNSAI Ds
Largest MarketNorth America

Biologic therapies remain the cornerstone of treatment in this market, offering targeted approaches that help control inflammation and prevent joint damage. These therapies are particularly effective for patients with moderate to severe disease and have become widely adopted in both developed and emerging regions. Innovation continues to be a critical factor in shaping the future of this market. Pharmaceutical companies are investing in next-generation therapies that offer improved safety profiles, reduced dosing frequency, and enhanced patient adherence.

Key Market Drivers

Growth in Healthcare Industry

The continued expansion of the global healthcare industry is playing a pivotal role in driving the growth of the psoriatic arthritis treatment market. The global healthcare industry generates annual revenues exceeding USD 4 trillion. The most substantial and profitable segments within the sector are pharmaceuticals and biotechnology, contributing nearly USD 850 billion, followed by medical technology and diagnostics, which generate over USD 400 billion. With increasing investments in healthcare infrastructure, rising patient awareness, and improved access to specialized care, the demand for effective treatment solutions for chronic autoimmune conditions like psoriatic arthritis is steadily rising.

As healthcare systems across both developed and emerging markets evolve, there is greater emphasis on early diagnosis, personalized medicine, and long-term disease management. More than 200,000 Ayushman Arogya Mandirs have been established nationwide to support early diagnosis and treatment. These centers provide millions of citizens with convenient access to screenings for diseases such as cancer, hypertension, and diabetes. This shift is particularly significant for psoriatic arthritis, a complex and progressive condition that requires comprehensive and sustained treatment strategies. The availability of advanced biologics, targeted therapies, and disease-modifying anti-rheumatic drugs (DMARDs) has expanded significantly as part of this healthcare evolution.

Key Market Challenges

High Treatment Costs & Financial Accessibility

One of the foremost challenges confronting the Global Psoriatic Arthritis (PsA) Treatment Market is the high cost associated with advanced therapies, particularly biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs). These innovative treatments, while clinically effective, command significant pricing often reaching tens of thousands of dollars annually per patient. This elevated cost structure poses substantial barriers to patient access, especially in emerging economies and underfunded healthcare systems.

The financial burden not only limits market penetration but also affects patient adherence and long-term treatment outcomes. Payers and insurers are increasingly scrutinizing reimbursement criteria, imposing stringent prior authorization processes that further complicate access. Consequently, patients may experience delays or outright denial of coverage for these essential therapies.

Key Market Trends

Rise of Biologics & Targeted Therapies

The global psoriatic arthritis treatment landscape is witnessing a significant transformation driven by the rapid adoption of biologics and targeted therapies. These advanced treatment modalities have emerged as the cornerstone of disease management, owing to their ability to specifically target underlying inflammatory pathways with enhanced efficacy and safety profiles compared to conventional therapies.

Biologics, including tumor necrosis factor (TNF) inhibitors, interleukin (IL)-17, and IL-23 inhibitors, currently command a substantial share of the market, reflecting their growing acceptance among clinicians and patients alike. In June 2025, Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced that Health Canada has granted a Notice of Compliance (NOC) for Yesafili (aflibercept). Yesafili, a biosimilar to Eylea (aflibercept) injection, is available in vial and prefilled syringe formats at a concentration of 2 mg/0.05 mL. This marks the first approval by Health Canada of a biosimilar to Eylea. Their precision mechanism of action not only improves clinical outcomes but also contributes to better quality of life for patients suffering from psoriatic arthritis.

Key Market Players

  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer, Inc.
  • UCB S.A.

Report Scope

In this report, the Global Psoriatic Arthritis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psoriatic Arthritis Treatment Market, By Drug Class:

  • NSAIDs
  • DMARDs
  • Biologics
  • Others

Psoriatic Arthritis Treatment Market, By Route of Administration:

  • Topical
  • Oral
  • Injectable

Psoriatic Arthritis Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psoriatic Arthritis Treatment Market.

Available Customizations:

Global Psoriatic Arthritis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Psoriatic Arthritis Treatment Market

5. Global Psoriatic Arthritis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (NSAIDs, DMARDs, Biologics, Others)
    • 5.2.2. By Route of Administration (Topical, Oral, Injectable)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Psoriatic Arthritis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Route of Administration
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Psoriatic Arthritis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Route of Administration
    • 6.3.2. Mexico Psoriatic Arthritis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Route of Administration
    • 6.3.3. Canada Psoriatic Arthritis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Route of Administration

7. Europe Psoriatic Arthritis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Route of Administration
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Psoriatic Arthritis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Route of Administration
    • 7.3.2. Germany Psoriatic Arthritis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Route of Administration
    • 7.3.3. United Kingdom Psoriatic Arthritis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Route of Administration
    • 7.3.4. Italy Psoriatic Arthritis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Route of Administration
    • 7.3.5. Spain Psoriatic Arthritis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Route of Administration

8. Asia Pacific Psoriatic Arthritis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Route of Administration
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Psoriatic Arthritis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Route of Administration
    • 8.3.2. India Psoriatic Arthritis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Route of Administration
    • 8.3.3. South Korea Psoriatic Arthritis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Route of Administration
    • 8.3.4. Japan Psoriatic Arthritis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Route of Administration
    • 8.3.5. Australia Psoriatic Arthritis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Route of Administration

9. South America Psoriatic Arthritis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Route of Administration
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Psoriatic Arthritis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Route of Administration
    • 9.3.2. Argentina Psoriatic Arthritis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Route of Administration
    • 9.3.3. Colombia Psoriatic Arthritis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Route of Administration

10. Middle East and Africa Psoriatic Arthritis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Route of Administration
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Psoriatic Arthritis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Route of Administration
    • 10.3.2. Saudi Arabia Psoriatic Arthritis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Route of Administration
    • 10.3.3. UAE Psoriatic Arthritis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Global Psoriatic Arthritis Treatment Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. AbbVie Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Amgen Inc.
  • 16.3. Johnson & Johnson Services, Inc.
  • 16.4. Bristol-Myers Squibb Company
  • 16.5. Novartis AG
  • 16.6. Eli Lilly and Company
  • 16.7. Pfizer, Inc.
  • 16.8. UCB S.A.

17. Strategic Recommendations

18. About Us & Disclaimer